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Abstract: Five years after the last prostatic carcinoma grading con-
sensus conference of the International Society of Urological Pathology
(ISUP), accrual of new data and modification of clinical practice re-
quire an update of current pathologic grading guidelines. This
manuscript summarizes the proceedings of the ISUP consensus
meeting for grading of prostatic carcinoma held in September 2019, in
Nice, France. Topics brought to consensus included the following: (1)
approaches to reporting of Gleason patterns 4 and 5 quantities, and
minor/tertiary patterns, (2) an agreement to report the presence of
invasive cribriform carcinoma, (3) an agreement to incorporate in-
traductal carcinoma into grading, and (4) individual versus aggregate
grading of systematic and multiparametric magnetic resonance
imaging–targeted biopsies. Finally, developments in the field of arti-
ficial intelligence in the grading of prostatic carcinoma and future
research perspectives were discussed.
Key Words: prostate cancer, grading, ISUP grade group, con-
sensus, minor grades, intraductal carcinoma, targeted biopsies
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The International Society of Urological Pathology (ISUP)last held a prostate cancer grading consensus conference in
2014 in Chicago,1 and the modifications from that conference
(summarized in Table 1) were incorporated into the 2016
World Health Organization (WHO) Classification of Tumours
of the Urinary System and Male Genital Organs blue book.2 In
the past 5 years, further data in the field of Gleason pattern
quantities, tumor growth patterns, and clinical practice advan-
cements such as widespread introduction of multiparametric
magnetic resonance imaging (mpMRI)-targeted biopsies or
fusion ultrasound/magnetic resonance imaging (MRI) biopsies
have added to challenges in reporting and grading for
pathologists. Furthermore, rapid developments in the field of
image analysis might influence daily pathology practice in the
near future. This accrual of new data has generated a need to
resolve several crucial matters in prostate cancer grading3 and
served as the impetus for a follow-up consensus conference.
This meeting was held on September 12, 2019, in Nice,
France, and the resulting recommendations are summarized
in the current manuscript (summarized in Table 2).
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ORGANIZATION OF CONSENSUS CONFERENCE
The conference was initiated and prepared by ISUP
council members (K.A.I., G.J.L.H.v.L., T.H.v.d.K., D.J.G.).
Topics were delegated to 4 working groups, who reviewed the
relevant literature and evidence on the following: (1) quanti-
tative grading, including assignment of Gleason patterns 4 and
5 percentages to biopsy and prostatectomy specimens, and
tertiary/minor patterns; (2) grading, significance, and reporting
of invasive cribriform and intraductal carcinoma (IDC);
(3) grade heterogeneity including grading based on the level
of the whole case, biopsy sites, and individual cores, and
reporting of targeted biopsies; and (4) the future of grading
including incorporation of artificial intelligence (AI) and
potential future grading scheme improvements. In total, 16
international prostate cancer experts from 4 continents
participated in the working groups, including 13 genito-
urinary pathologists, 1 urologist (N.M.), 1 radiologist
(I.G.S.), and 1 image analysis expert (G.L.).
A premeeting online survey with 31 questions was held
open to the ISUP membership for 34 days and generated 252
complete responses; by continent: North America 39%, Europe
34%, South America 11%, Asia 10%, Australia 5%, and Africa
1%. The survey results informed the working groups with data
on current clinical practice and identified controversial topics to
be clarified in the consensus meeting, or in future meetings in
case reasonable scientific evidence was still lacking.
The conference meeting was attended by 93 participants
(Appendix). Each working group presented a detailed literature
review of its topics, provided an overview of the relevant survey
outcome, and put proposal statements to the meeting. Twenty-
three statements were voted upon in an agree/disagree manner
using a VoxVote.com application. Consensus on a proposal
statement was considered to be met when at least two thirds
(67%) of the voters agreed.
QUANTITATIVE GRADING, WORKING GROUP 1
Percentage of High-grade Gleason Patterns
The premeeting survey indicated that 93% of re-
spondents reported both the Gleason score (GS) and the IS-
UP 5-tier grading system as recommended at the 2014 ISUP
consensus meeting1 further labeled here as (ISUP) grade
group (GG). Although GS (GG) is a standard prognostic
measure, the extents of higher grade patterns 4 and 5 affect
patient outcomes and could influence management decisions.4
By separating GS 7 cancers into 3+4=7 (GG2) and 4+3=7
(GG3), the proportion of pattern 4 is at least partly in-
corporated into patient management algorithms.5–7 However,
a number of studies have shown that further quantification of
pattern 4 has clinical significance.8–13 For instance, biopsy
specimens with GS 3+4=7 in which the greatest amount of
pattern 4 was <5% of the tumor volume in any one core had
similar prostatectomy findings and biochemical recurrence-
free survival to GS 3+3=6 cases in a recent study.7 If other
clinical variables are favorable, some GS 3+4=7 (GG2) pa-
tients with limited amounts of Gleason pattern 4 may qualify
for active surveillance.14–16 In radical prostatectomy speci-
mens, a higher percentage of Gleason pattern 4 and even
limited amounts of pattern 5 have been associated with in-
creased biochemical relapse.17,18 The 2016 WHO Classi-
fication, College of American Pathologists, and the
International Collaboration of Cancer Reporting (ICCR)
dataset recommend reporting of pattern 4 percentage for GS
7 in biopsies and radical prostatectomies, although no precise
methodology is specified.2,19 Reporting the percentage of
pattern 5 is currently not a requirement.
The premeeting survey showed that 49% of the re-
spondents reported percentage Gleason patterns 4 and 5 in
radical prostatectomies, irrespective of GS. Overall, 33%
reported a percentage only for GS 7, either 3+4=7, 4+3=7, or
both (9%, 3%, and 21%, respectively). For biopsies, 44% gave
the percentage for all carcinomas, whereas a similar number
did so only for GS 7, either for 3+4=7, 4+3=7, or both (13%,
2%, and 29%, respectively). Also, grading of minute cancer foci
in biopsies as, for example, GS 4+4=8 may result in over-
grading and overtreatment. Grading of limited foci does not
correlate well with pathologic stage and has been associated
with downgrading in radical prostatectomy specimens.20–22
Moreover, assessment of percentage pattern 4 in minute cancer
foci has poor reproducibility, particularly for poorly formed
glands.23–27 Although this topic was not discussed in depth at
the meeting, the literature suggests restraint in grading minute
(<1mm) foci of Gleason patterns 4 or 5 cancer, possibly by
adding a comment that the specimen vial grade may over-
estimate the grade of the entirety of the cancer.
TABLE 1. ISUP 2014 Modifications to Growth Patterns and
Grade Grouping of Prostatic Carcinoma1
Assign cribriform glands as Gleason pattern 4, irrespective of size
Assign glomeruloid glands as Gleason pattern 4, irrespective of size
Grade mucinous carcinoma of the prostate based on its underlying
growth pattern rather than grading them all as pattern 4
Do not assign a Gleason grade to IDC of the prostate without invasive
carcinoma. Make a comment on its very strong association with
aggressive prostate cancer
Use the 2014 modified 5-tier grading system1 in conjunction with the
Gleason system
TABLE 2. Summary of ISUP 2019 Modifications to Prostate
Cancer Grading
Report in biopsies the percentage Gleason pattern 4 for all GS 7 (ISUP
GG 2 and 3)
For radical prostatectomies, include the presence of tertiary/minor
Gleason patterns 4 and 5 in the GS, if constituting > 5% of the tumor
volume
Report in radical prostatectomies presence of tertiary/minor Gleason
patterns 4 and 5
Do not grade IDC without invasive cancer
Incorporate the grade of IDC into the GS when invasive cancer is present
Comment on the presence and significance of IDC in biopsies and radical
prostatectomy specimens
Comment on the presence and significance of invasive cribriform cancer
in biopsies and radical prostatectomy specimens
Report in systematic biopsies a separate GS (ISUP GG) for each
individual biopsy site
Report in mpMRI-targeted biopsies a global (aggregate) GS (ISUP GG)
for each suspicious MRI lesion
Report specific benign histologic findings in suspicious (PIRADS 4-5)
MRI-targeted biopsies without cancer
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Minor/Tertiary Patterns
The presence of minor/tertiary patterns was considered
separately for biopsy and radical prostatectomy specimens. For
biopsies, the ISUP has recommended the inclusion of tertiary
higher grade patterns in the GS, irrespective of extent, since the
2005 consensus meeting.28 Thus, a needle biopsy with 60%
Gleason pattern 4, 36% pattern 3, and 4% pattern 5 would be
reported as GS 4+5=9 (GG5). It has since been suggested that
use of the term “minor” rather than “tertiary” is preferable
because the primary and secondary grades may be identical,
with a very small second higher grade cancer component.29
The presence of a minor component of Gleason pattern 5 in
GS 4+3=7 cancer at biopsy predicted higher tumor volume at
prostatectomy.30 Sauter et al18 showed that incorporation of
minor patterns into a quantitative grading model at biopsy
improved the prediction of prostatectomy pathology. In-
corporation of minor high-grade patterns in the biopsy GS
ensures that they are accounted for when considering patients
for active surveillance.
In radical prostatectomy specimens, the preferred
approach to reporting minor patterns has remained uncertain.
It was agreed in 2005 to assign GS based only on the primary
and secondary patterns with a comment on the presence of any
minor pattern.28 However, neither the 2005 nor 2014 meetings
recommended a percent cutoff for a minor pattern. A minor
pattern that can technically range from 1% to 32% is excluded
from current prognostic tools; therefore, a significant volume of
Gleason pattern 5 may be ignored clinically. Although 5% is a
somewhat arbitrary cutoff, several studies suggest that <5%
Gleason pattern 4 is not associated with increased risk of
biochemical recurrence or adverse pathology at prostatec-
tomy,31–33 although a few others contradict this.34–37 The
situation for Gleason pattern 5 is different, making it more
discriminatory than Gleason pattern 4.38 Multiple studies have
shown that any minor component of Gleason pattern 5 wor-
sens biochemical recurrence-free survival.4,18,31–33,38–42 Small
amounts (mostly <5%) of minor Gleason pattern 5 generally
worsen the prognosis of the baseline GS,43 but reports disagree
on whether a minor component warrants promotion to the
next higher GS.18,39–42
In the premeeting survey, for carcinomas with 60%
primary Gleason pattern 3, 36% secondary pattern 4, and
4% pattern 5, 86% of the respondents would report a GS
3+5= 8 on biopsy, whereas only 7% would do this for
prostatectomy. In prostatectomies with 60% pattern 3, 30%
pattern 4 and 10% pattern 5, 66% would report a GS 3+5=8
and 30% would report as 3+4=7, with or without a comment
on the presence of minor pattern 5. Discussion revealed a
concern that inclusion of <5% pattern 5 in the GS could blur
the definition of high-grade cancers because the finding of focal
single cells carries poor reproducibility,44 a point that sig-
nificantly influenced the proposal and subsequent vote.
Proposals and Voting
At the meeting, a consensus emerged in favor of re-
porting percentage of Gleason pattern 4 for all GS 7 (GG 2, 3)
biopsies, but there was no consensus to do so for radical
prostatectomies (Table 3). Subsequent votes affirmed the
current use29 of the “<5% rule” for reporting minor patterns
in prostatectomy specimens, which is different from its use in
biopsies. Similar to previous policy, any highest Gleason
patterns 4 or 5 present in a radical prostatectomy must account
for at least 5% of the tumor to be incorporated as a secondary
pattern of the GS. Hence, in radical prostatectomy specimens,
60%Gleason pattern 3, 37% pattern 4, and 3% pattern 5 would
be reported as GS 3+4=7 (GG2) with minor/tertiary pattern 5,
whereas 60% pattern 3, 30% pattern 4, and 10% pattern 5
would be reported as GS 3+5=8 (GG4). The same rule also
applies to cases with predominant Gleason pattern 3 and minor
high-grade foci.
IDC AND TUMOR GROWTH PATTERNS,
WORKING GROUP 2
Intraductal Carcinoma
IDC is characterized by extension of cancer cells into
preexisting prostatic ducts and acini, distending them, with
preservation of basal cells. At least 3 conflicting definitions
of IDC have been given.45–47 Cohen et al46 state that duct
diameter must exceed 2 times that of benign peripheral zone
glands, and add minor criteria of right-angle branching,
smooth contours, and dimorphic cell population with only
central cells being prostate-specific antigen–positive. All defi-
nitions include trabecular, cribriform, and solid/comedo
TABLE 3. Grade Quantification Voting Results
Statement Voting Result
Percent Gleason pattern 4 should be reported in biopsy for score 3+4= 7 100% agree
Percentage Gleason pattern 4 should be reported in biopsy for score 4+3= 7 94% agree
Percent Gleason patterns 4 and 5 should be reported for all radical prostatectomies 42% disagree, no consensus
For radical prostatectomy, any amount of Gleason pattern 5 ≥ 5% should be included in the GS as the secondary
pattern
77% agree
For radical prostatectomy, any amount of Gleason pattern 4 ≥ 5% should be included in the GS as the secondary
pattern
79% agree
For radical prostatectomy, any amount of Gleason pattern 4 < 5% should be reported as “minor pattern,” but not
included in the score
72% agree
For radical prostatectomy, any amount of Gleason pattern 5 < 5% should be reported as “minor pattern,” but not
included in the score
85% agree
For radical prostatectomy, any amount of Gleason pattern 5 < 5% should be included in the score as the secondary
pattern
67% disagree, consensus against
For radical prostatectomy, any amount of Gleason pattern 4 < 5% should be included in the score as the secondary
pattern
66% disagree, no consensus
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patterns, but Guo et al47 add a papillary pattern without fi-
brovascular cores. Guo and colleagues, overlooking the above
additions of Cohen and colleagues, also stipulate that if growth
is papillary or loose cribriform, there must be nuclear size at
least 6× normal, or comedonecrosis. Two recent studies have
shown that in many instances where cribriform or solid fields
with comedonecrosis were morphologically considered invasive
Gleason pattern 5, there were in fact surrounding basal cells
by immunostaining, suggesting that comedonecrosis is often
a manifestation of IDC.48,49 Although the definition of
Guo and colleagues is part of the 2016 WHO blue book, it
was agreed that a separate meeting is needed to resolve defi-
nitional ambiguities.50,51 Many groups have reported an in-
dependent adverse prognostic value of IDC in biochemical
recurrence-free survival and cancer-specific survival of prostate
cancer patients on the basis of biopsy and radical prostatec-
tomy specimens.52,53
IDC typically occurs adjacent to high-grade invasive
carcinoma and only rarely is unaccompanied by invasion. The
invasive component might be GS 6 to 10 (GG1 to 5). IDC has
been reported without an invasive component in 0.06% to
0.26% of prostate biopsies.53–55 The 2014 ISUP Gleason
grading consensus conference1 recommended that IDCwithout
invasive carcinoma should not be assigned a GG and this
proposal was endorsed in the WHO 2016.53 This endorsement
was done without voting separately on the very different
scenarios of IDC encountered with and without invasive car-
cinoma at the 2014 ISUP consensus conference.1 The current
consensus conference considered these scenarios separately be-
cause different rules may apply to both scenarios.
The premeeting survey disclosed that 90% of the re-
spondents would not assign a Gleason grade to pure IDC in
the absence of an invasive component, and 76% to 81% would
not grade IDC if present adjacent to GS 3+3=6 (GG1) cancer,
in accordance with the 2014 ISUP and 2016 WHO guidelines.
However, 65% of the respondents felt that IDC could not be
reliably diagnosed without immunohistochemistry and 67%
indicated that they would consider a scheme by which IDC
associated with invasive cancer can be incorporated into the
GS instead of exclusively mentioning it separately. IDC
without invasive carcinoma in biopsies, conversely, usually is
an epiphenomenon of an unsampled, high-grade invasive
component.53 There is currently no clinical consensus that
patients with biopsies showing only IDC should be managed
with radical therapy as opposed to urgent rebiopsy.
IDC With Invasive Carcinoma
It may be argued that incorporating IDC adjacent to
invasive cancer into the GS could result in overgrading
since Khani and Epstein55 found that 3 (21%) of 14 patients
with the unusual scenario of IDC andGS 6 on biopsy had only
GS 6 cancer in their radical prostatectomy specimens. These 3
patients’ prostatectomy specimens were, however, only partially
submitted for histologic examination, precluding exclusion
of unsampled higher grade cancer.55 Among 62 patients with
biopsies showing GS 6 associated with IDC, 7% had metastasis
at presentation, 13% of men who received radical therapy
ultimately progressed to metastatic cancer, and 55% of the 11
(18%) men initially put on surveillance were actively treated
because of progressive cancer,55 which is clearly different from
patients with biopsy GS 6 only.3
Several compelling arguments support incorporating
IDC associated with invasive cancer into the GS. First, all
historical and contemporary GS outcome data, including those
used in multiple clinical phase 3 trials, are based on morphol-
ogy without application of routine immunohistochemical basal
cell staining, setting a precedent for incorporating IDC into the
GS. Although a majority of urologic pathologists surveyed
(62% to 78%) would not include IDC in the overall GG
assessment in diagnostic biopsies, 59% do include intermingled
IDC in the quantification of percentage/linear core involve-
ment; 59% to 88% do rarely if ever perform basal cell im-
munohistochemistry for distinguishing IDC from invasive
carcinoma; and 95% believe that GG1 cancer with IDC should
be a contraindication to active surveillance.56
Second, there is general agreement that basal cells are not
always identifiable by hematoxylin-eosin stain alone. In fact,
distinction of IDC from invasive carcinoma by basal cell im-
munostaining might even be impossible. It is well known that
some high-grade prostate intraepithelial neoplasia (PIN) glands
lack a basal cell layer on routine tissue sections probably due to
sampling artifact; the same may be true for IDC, which can
have an even more dispersed basal cell layer owing to gland
distention. It is also uncertain how to interpret morphologically
irregularly invasive cribriform structures with sporadic basal
cells (Fig. 1). A survey in which 38 photomicrographs were
circulated to 39 genitourinary pathologists disclosed only 43%
consensus for an unequivocal diagnosis of IDC.57 Varma
et al50 surveyed 23 genitourinary pathologists and found consi-
derable variation in the diagnostic criteria and rules used to
report IDC. Thus, excluding IDC from grading carries the risk
of undergrading a cancer equivalent to 4+3 as 3+4 or 3+3. If
IDC also has comedonecrosis, grading disparities might
become even greater. Rates of immunostaining use vary
among different laboratories, but incorporating IDC into the
GS obviates the requirement to perform immunostaining in
most cases. The number of additional immunostain procedures
to discriminate IDC from invasive cancer could be limited if
applied only for those cases in which immunostaining outcome
would affect the GS. However, recommendations of the 2016
WHO, ICCR, and the current consensus meeting to report
percentage Gleason pattern 4 in all heterogenous GS 7 tumors
would in fact require performing immunostaining in signifi-
cantly more cases, as IDC would have to be excluded from
Gleason pattern quantification because it would be contra-
dictory not to incorporate IDC into tumor grading, but to
include it in Gleason pattern quantification.3 Older studies
(before 2014) did not use immunostaining to distinguish IDC
because IDC was not recognized broadly as an independent
prognosticator. Instead, comedonecrosis was just graded as
Gleason pattern 5 cancer, when much of it was IDC. Also,
requiring immunohistochemistry to avoid overgrading cancer
may result in Gleason scoring not being feasible in countries
having no or limited access to this technique, and in interpretive
problems: are rare basal cells permitted in invasive cancer?
Third, recent evidence has shown that incorporation of IDC
and invasive cribriform cancer into the GG improved the
predictive value of the system for cancer-specific survival and
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metastasis-free survival.58 It is noteworthy that IDC carries an
association with germline mutations in genes mediating DNA
repair.59 The latest National Comprehensive Cancer Network
guideline recommends taking IDC detected on biopsy into
account for the genetic testing of germline variants including
BRCA1 and BRCA2, and this may influence our practice.60
Fourth, many clinicians might disregard any comment on IDC
presence in considering therapy. In the series reported by Khani
and colleagues, 11 (18%) of the 62 patients were inappro-
priately placed on active surveillance despite the pathology
reports’ inclusion of a note highlighting that IDC is a high-
grade cancer. Thus, presenting IDC outside the GS may result
in using only the score for management and make some
patients inappropriately eligible for active surveillance. Cancer
registries around the world do not record the presence of IDC;
thus, the important information inherent in its presence would
be lost by not incorporating the finding into the GS. It is
noteworthy that this was the rationale for incorporating a
minor component of a higher grade pattern into the biopsy GS
rather than conveying this information in an accompanying
note.1
Proposals and Voting
There was 91% consensus that IDC without invasive
carcinoma should not be graded (Table 4). It was proposed
that IDC associated with invasive carcinoma should be
incorporated into the GS. Overall, 76% voted in favor of this
proposal. Thus, without having to perform immunohisto-
chemistry, cribriform IDC with invasive carcinoma should be
graded as a Gleason pattern 4 component, and solid pattern
IDC or IDC with comedonecrosis should be assigned Gleason
pattern 5. Furthermore, assignment of a grade to IDC implies
that IDC can be included in Gleason pattern 4 or 5 quanti-
fication and tumor volume assessment. Because IDC is likely to
have prognostic significance independent of the GS, 83% of the
participants agreed that the presence and significance of IDC
FIGURE 1. Cribriform epithelial proliferations showing overlap between IDC and invasive cribriform Gleason pattern 4. A and B,
Two adjacent cribriform proliferations, one (left) having scattered basal cells, the other (right) without basal cell layer. The left
structure fulfills the criteria of IDC. The right structure may represent either invasive cribriform carcinoma, or IDC without basal cells
due to sampling artifact in this section. C and D, Cribriform proliferation with a basal cell layer compatible with IDC with irregular
tubular outgrowths. Classification of outgrowth is unclear as either IDC, IDC transitioning to Gleason pattern 3, or IDC and invasive
cribriform carcinoma. A and C, hematoxylin-eosin; B and D, high molecular weight cytokeratin.
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should be commented on, despite incorporating IDC into
the GS.
Tumor Growth Patterns
Gleason pattern 4 has been expanded from its 1966
definition61 and now comprises a heterogenous group of tu-
mors with poorly formed, fused, cribriform, and glomeruloid
glandular structures.1,28 Starting with Iczkowski et al,62 nu-
merous studies have shown that patients with cribriform pat-
tern 4 in both biopsies and radical prostatectomies have worse
biochemical recurrence-free survival, metastasis-free survival,
and cancer-specific survival than those without.63,64 Although
the value of cribriform growth has mostly been studied for GS
7 patients,65 it also has independent prognostic value in men
with GS 8 (GG4) prostate cancer.27,65 Its role in GS 9 prostate
cancer is uncertain, although cribriform growth holds a strong
independent association with the presence of GG5.62 Relevant
molecular differences, such as significantly more frequent
PTEN and p27 loss at the RNA and protein levels, have been
found in cribriform as opposed to noncribriform Gleason
pattern 4 cancer.66 However, most studies on cribriform
carcinoma do not explicitly state whether and how invasive
cribriform carcinoma was distinguished from IDC. In a series
of 1031 biopsies with additional immunohistochemical staining,
Kweldam et al65 found that both IDC and invasive cribriform
carcinoma had added predictive value for cancer-specific sur-
vival. In 2017, Roobol et al67 published a study on including
cribriform pattern 4 in the ERSPC risk calculator. In this study,
it was shown that by inclusion of the cribriform pattern, the
definition of clinically significant cancer improved. Given its
independent adverse prognostic value, invasive cribriform car-
cinoma is considered in therapeutic decision-making together
with IDC in an increasing number of institutions. In the pre-
meeting survey, 52% of the respondents stated that they re-
corded the presence of cribriform cancer in biopsy and 44% in
radical prostatectomy reports.
Proposals and Voting
Overall, 93% of the participants agreed that cribriform
Gleason pattern 4 had worse prognosis than poorly formed or
fused Gleason pattern 4 (Table 4). Furthermore, 97% agreed
on commenting on the presence of cribriform pattern 4 in GS 7
and 84% in GS 8 prostate cancer cases at biopsy and radical
prostatectomy.
GRADE HETEROGENEITY, WORKING GROUP 3
Grading of Multifocal Prostate Cancer at Radical
Prostatectomy
Detailed morphometric studies have found multifocality
in 68% to 87% of radical prostatectomy specimens.68–70 Wise
et al69 measured separate tumor volumes and found that the
vast majority of additional tumors had a tumor volume of
<0.5mL. In a comparison of progression rates, they noted that
the presence of additional tumors did not worsen outcome.
Also, index tumor size was inversely correlated to the number
of additional tumors, which might be explained by the fact that
smaller tumors are readily separable. In conclusion, the authors
recommended use of the largest tumor to estimate prognosis.
The definition of the index tumor was debated at the
2009 ISUP consensus conference on handling and reporting
of prostatectomy specimens, in Boston. At that meeting,
there was no consensus on whether index tumor was de-
fined by size, size and grade, or size and stage.71 Huang
et al10 analyzed in detail the relationship of the index tumor
with GS and pT stage in a series of 201 prostatectomies,
and confirmed that the largest nodule defined the behavior
of the tumor. In 89% of multifocal cases, the highest GS,
tumor volume, and stage were seen in the index tumor. In
the premeeting survey, 60% of the respondents stated that
they graded spatially distinct tumors separately, and only
38% would recommend using one global GS, merging the
grades of multifocal tumors, as standard.
Proposal and Voting
In grading radical prostatectomy specimens with
multifocal tumors, 67% consensus was reached to report
the GS of the (a) largest, (b) highest stage, and (c) highest
grade tumor if these are not one and the same. There was
further consensus (67%) that a global GS would, in most
instances, be sufficient for patient management (Table 5).
TABLE 4. IDC and Tumor Growth Pattern Voting Results
Statement
Voting
Result
Pure IDC should not be graded 91% agree
In cases with invasive carcinoma, IDC should be
incorporated into the GS
76% agree
If IDC is incorporated into the GS, then its presence
and significance should be commented on
83% agree
Cribriform Gleason pattern 4 has worse prognosis
than poorly formed or fused pattern 4
93% agree
Presence of invasive cribriform cancer should
be commented on in GS 7 cases
97% agree
Presence of invasive cribriform cancer should
be commented on in GS 8 cases
84% agree
TABLE 5. Grade Heterogeneity Voting Results
Statement Voting Result
In grading radical prostatectomy specimens with
multifocal tumors, GSs of (a) largest, (b)
highest stage, and (c) highest grade tumor
should be reported separately if the above
are not identical
67% agree
In prostatectomy specimens, irrespective of
multifocality, a global GS should be sufficient
for further patient management
67% agree
In systematic prostate biopsies, a GS should be
assigned to each individual biopsy site
80% agree
In grading of targeted prostate biopsies, a
separate GS should be assigned for each core
81% disagree,
consensus against
In systematic prostate biopsies, a global GS
should be assigned
54% agree, no
consensus
In MRI-targeted biopsy samples, a global GS for
each suspicious MRI lesion should be assigned
78% agree
In biopsy cases involving inequality of GS for
systematic and targeted biopsy samples, a
global grade should be assigned
41% agree, no
consensus
Benign histologic findings in targeted biopsies of
high-suspicion lesions (PIRADS 4-5) that are
negative for cancer should be reported
78% agree
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Heterogenous Grades of Prostate Cancer in
Biopsy Specimens
Whenever carcinoma is present in multiple cores of one
biopsy session, dissimilarities of GS are frequently encountered
among biopsies. Risk stratification and patient management
might subsequently be based either (1) on the biopsy with the
highest/worst GS or (2) on a global/overall GS taking into
account Gleason pattern quantities of all positive biopsies to-
gether. A consensus was reached at the 2005 ISUP consensus
conference on a proposal to assign separate scores for each
container of specimens (unless different color inks were used),
but there was no consensus on whether to score multiple cores
per single container separately.28 The use of the highest score
may cause grade inflation in 14% to 51% of cases, but 78% of
urologists prefer to rely on the highest score,72 believing that
when tumor is multifocal, behavior is driven by the highest
score. The premeeting survey showed that 85% of the re-
spondents reported that the GS per individual biopsy in case
systematic biopsies revealed dissimilar grade on the right and
left sides, and 27% would additionally report a global GS.
Several studies have analyzed the prognostic value of global
versus highest GS in biopsies. Earlier studies found the highest
grade to be more predictive of tumor stage and grade in
prostatectomy specimens.73,74 Tolonen et al75 reported that
both approaches were equal predictors of biochemical re-
currence in patients treated by hormone ablation. Some con-
temporary studies showed no statistically significant differences
between global and highest biopsy GS, although some suggest
a slight superiority of global grade75–80 (but they tend to be
identical in >90% of cases81). However, because little in-
formation is provided about potential multifocality and about
the exact grading methodology in reporting prostatectomies in
these studies, it is unclear what GS was used for comparison.
This could explain the increased rates of concordance of
globally graded biopsies and globally graded prostatectomy
specimens.
The critical problem of current biopsy grading practice is
the lack of integration of imaging information that would allow
determination of whether topographically different biopsies
represent different ends of the same tumor focus and may thus
be lumped into a global grade. With the wider use of mpMRI,
clinical practice is changing rapidly. The PRECISION trial has
demonstrated that mpMRI-based biopsies outperform classic
systematic transrectal ultrasound–guided biopsies in cancer
detection rate.82 Patients increasingly ask for MRI before
having a classic transrectal ultrasound–guided biopsy and
clinicians are more open to defer or omit a biopsy, if the
mpMRI yields PIRADS scores ≤2. Comparison of sensitivity
for GG ≥2 cancer detection in biopsy-naive men and men
with a previous negative biopsy shows that targeted biopsies
are superior to systematic biopsies.83,84 Targeted biopsies usu-
ally provide a higher core length of cancer than standard bi-
opsies, which better predicts radical prostatectomy findings.85
Furthermore, extraprostatic extension is better predicted by GS
of targeted biopsies than of systematic biopsies.86 Gordetsky
et al87 showed that aggregate GS (and cancer extent) for tar-
geted biopsies better predicted tumor volume and ex-
traprostatic extension than grading (and extent) in the worst
single core. Zhao et al88 found that targeted biopsy GS’s were
less likely to be upgraded at prostatectomy.
False-positive mpMRI findings remain problematic,
especially in younger patients, because they might lead to
patient anxiety, and raise the question of potentially false-
negative biopsies missing a high-grade tumor.89 In-
flammation and granulomas are sometimes confused with
prostatic carcinoma on mpMRI, depending on clinician
inexperience. Reporting of these non-neoplastic findings
can help explain false-positive mpMRI findings and assist
patient management.
Proposal and Voting
At discussion, it appeared that systematic and/or targeted
biopsy grading practices significantly varied among labo-
ratories and were incited by the number of biopsies that
were submitted in one container, local clinical demands,
and topographical differences. At the conference, 80% of the
participants agreed that in systematic biopsies, a GS should
be assigned to individual biopsy sites when multiple cores are
submitted together in one vial. There was no consensus (54%)
on reporting one global GS for systematic biopsies. Figure 2
summarizes the special recommendations applying to MRI-
targeted biopsies. Overall, 78% voted for providing a global GS
for each suspicious MRI lesion, whereas 81% voted against
grading each targeted biopsy core separately. Participants did
not agree (41%) to provide a global GS in case the systematic
and targeted scores were unequal. Amajority of 78% agreed on
reporting of benign histologic findings when targeted biopsies
of suspicious MRI lesions (PIRADS 4 to 5) are nonmalignant
(Table 5).
FUTURE OF PROSTATE CANCER PATHOLOGY,
WORKING GROUP 4
AI in Prostate Pathology
The emergence of whole-slide scanners and AI-based
tools in prostatic pathology has several benefits. Fully digital
workflows combined with AI bring the capability to store,
manage, and analyze digital data in a high-throughput manner.
Pathologists are facing an increasing number of prostate
biopsies with an expectation of rapid turnaround and highly
nuanced reporting. These problems are coupled with widely
appreciated interobserver variability in Gleason grading of
prostate cancer, particularly at key clinical decision points such
as GG1 versus GG2, and lack of subspecialty expertise
required to achieve optimal grading precision makes machine
learning (ML)-based tools an obvious option to optimize
clinical decision-making. The preconference survey indicated
that ISUP members have a generally positive view of AI
as applied in prostatic pathology. Specifically, 31% of the
respondents indicated that they had participated in ML proj-
ects focused on prostate cancer detection and/or grading, and
71% believed that there was a role for ML in screening, deci-
sion support, and improving efficiency over the next decade.
Finally, 74% would use ML tools to screen prostatic biopsies,
provided there was no cost barrier to implement validated
algorithms that function at the same level as an experienced
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genitourinary pathologist, whereas only 2% believed that ML
would replace most of a pathologist’s work. ML models for
prostatic pathology published to date include those designed to
detect carcinoma, measure the extent of tissue involvement by
tumor, and perform Gleason grading at the level of expert
genitourinary pathologists.90–92
Prostate Cancer Detection
In 2016, Litjens et al90 devised the first published al-
gorithm designed to detect prostatic carcinoma in whole-
slide images of core biopsies resulting in a receiver operator
characteristic area under the curve (ROC-AUC) of 0.99 for
distinguishing malignant from benign in an independent set
of 270 biopsy slides. This algorithm could confidently screen
30% to 40% of prostate biopsies as benign without addi-
tional human intervention. A subsequent algorithm based
on over 24,000 prostate biopsy slides developed by Cam-
panella et al91 using a weakly supervised approach without
laborious annotation by pathologists obtained a ROC-AUC
of 0.991. They concluded that their algorithm could remove
65% to 75% of biopsy slides from pathologist review with
100% sensitivity for case-level cancer detection. Im-
portantly, these investigators demonstrated the general-
izability of their algorithm on an external slide set. Another
group92 reported a ROC-AUC of 0.997 on digitized slides of
8313 biopsies from 1222 patients in the Swedish 2012-2015
STHLM3 study with no false positives. Their algorithm
missed 3 small foci of carcinoma in 721 cores, all cancer foci
under 0.5 mm in size. They also reported a correlation of
0.96 between their algorithm and the study pathologist with
respect to linear measurement of the carcinoma in cores.
Gleason Grading
AI can create algorithms allowing generalists to func-
tion at the subspecialist level. Nagpal et al93 used a classic
supervised learning approach to develop a deep learning
system (DLS) for Gleason grading on radical prostatectomy
specimens from 3 different sources. Accuracy was assessed for
the assignment of GG by 29 generalist pathologists relative to
a panel of 3 genitourinary subspecialists. The DLS out-
performed the generalists with a mean accuracy of 0.70 ver-
sus 0.64. Although on prostatectomy slides of The Cancer
Genome Atlas (TCGA) grading performance in relation to
clinical outcome of a DLS algorithm was inferior to a panel
of 3 subspecialists, it was superior to the 29 generalists for this
task.93 Nordström et al94 assessed the grading performance of
their algorithm compared with cases scored by a panel of 23
international ISUP subspecialists in the Imagebase project.95
The AI model performed within the range of the sub-
specialists, with an average κ value of 0.62. Bulten et al96 used
5759 digitized biopsies from 1243 patients to develop a GS
algorithm based on a semiautomated approach using cores
with pure Gleason patterns 3, 4, or 5, and the resulting model
was adapted for reviewing biopsies with mixed patterns like
FIGURE 2. Schematic overview of reporting systematic and mpMRI-targeted biopsies. GP indicates Gleason pattern.
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3+4. On a test set of 550 biopsies, their system achieved high
agreement with consensus review by 3 subspecialists (Cohen
κ=0.918). These examples clearly demonstrate the potential
of AI to improve efficiency through prescreening of prostate
biopsies to filter out benign biopsies and to improve quality
by providing expert-level decision support for Gleason
grading, particularly at critical clinical thresholds. Despite the
promising results of AI in diagnosing, quantifying, and
grading of prostate cancer, several major challenges must be
addressed before above AI tools can assume routine clinical
use. These include demonstrating generalizability, obtaining
regulatory approval, validating against clinical outcome, and
being able to handle biopsies that contain nonprostatic neo-
plasms such as urothelial or rectal carcinoma, or lymphoma.
FUTURE PERSPECTIVES
Many studies support the added predictive and prog-
nostic value for percentage Gleason pattern 4, minor high-
grade patterns, IDC, and invasive cribriform carcinoma, as
reflected by the current ISUP consensus conference. Reporting
of these histopathologic findings is therefore recommended.
Clinicians, however, may be less cognizant of the practical
impact of these morphologic findings on individual patients’
risk stratification. For instance, many studies have shown that
GG2 prostatic carcinoma patients without invasive cribriform
carcinoma and/or IDC have less aggressive cancer than those
with these features, but it is not yet clear whether their clinical
outcome approaches that of men with GG1 cancer. Kweldam
and colleagues65,97 found that men with biopsy GG2 without
cribriform architecture had similar cancer-specific and post-
operative biochemical recurrence-free survival to those with
GG1. If the excellent outcome of patients with GG2 without
cribriform can be validated in cohorts that have not undergone
subsequent radical therapy, it might have a major impact for
active surveillance eligibility. More studies comparing clinical
and pathologic outcomes between newly defined subgroups are
necessary to improve individual risk stratification.
Comprehensive modification of the current grading
system incorporating these pathologic features might have
significant clinical impact, if its predictive value and reprodu-
cibility can outperform current Gleason grading. In the pre-
meeting survey, the majority of respondents were open to
altering the current GS/GG system incorporating the recently
recognized prognostic factors, but 63% of the respondents
considered that more validation was needed before actually
changing the grading system. A few grading system mod-
ifications have been proposed in recent years. Iczkowski et al64
proposed adding the suffix “C” to define GG 2C, 3C, and 4C
signifying that cribriform cancer is present; GG 2, 3, and 4
without C would signify absence of cribriform cancer. While
being comprehensive and easy to implement, this would change
the current 5-tier to an 8-tier grading system, and as stated
previously, it is not clear whether a difference in clinical out-
come exists for instance between GG 2C and 3. In a large
radical prostatectomy cohort, Sauter et al38 showed that a
continuous scale quantifying percent pattern 4 and 5 out-
performed Gleason grading. An important advantage of this
model is that interobserver variability in grading has less impact
than with current Gleason grading/Grade grouping. A dis-
advantage of this system is the complexity of the grading
scheme leading to a continuous risk scale from 0 to 117.5,
which would require additional cutoff definitions for practical
clinical decision-making. van Leenders et al58 showed that re-
ducing the GG by one point if no invasive cribriform or IDC
were present at biopsy led to better discriminative value of the
GG for cancer-specific mortality. This improvement was at-
tributable mainly to the overall good outcome of GG2 patients
without cribriform architecture, whereas its value in higher GG
is less pronounced.
A caveat in most of the studies to date is that they in-
vestigate only one pathologic feature, such as percent Gleason
pattern 4, minor patterns, invasive cribriform, and/or IDC. It is
not clear yet to what extent each of these features holds in-
dependent predictive value if analyzed together with the other
features as covariates. In GG2 biopsies, the presence of invasive
cribriform and/or IDC correlated with incremental percent
Gleason pattern 4; it occurred in 6% of men with 1% to 10%
Gleason pattern 4, in 22% with 10% to 25% pattern 4, and in
44% of patients with 25% to 50% pattern 4.98 In multivariate
analysis, cribriform architecture was an independent predictor
for postoperative biochemical recurrence-free survival, whereas
percent Gleason pattern 4 as a continuous variable was not.
Studies on the interaction of these pathologic variables and
their independent predictive values are warranted to identify the
most important features, and incorporate those into an im-
proved and reproducible grading system.
Because invasive cribriform and IDC have independent
prognostic value and can support individual therapeutic deci-
sion-making, it is important that their diagnostic characteristics
and distinguishing features are well defined. Among Gleason
grade 4 growth patterns, interobserver agreement is best for
glomeruloid and cribriform architecture, but is significantly
worse for poorly formed and fused glands.99,100 It is, however,
not defined yet as to what are the exact distinguishing features
of cribriform growth pattern and (1) distended glomeruloid
glands with large intraluminal protrusions, and (2) large com-
plex fused glands.100 The premeeting survey revealed that a
large range of pathologic features were used for differentiating
large glomeruloid, fused, and cribriform glands. Similarly, dif-
ferentiating features of IDC and high-grade PIN need a clearer
distinction.50,57 A subgroup of intraglandular lesions falling
short of IDC, but exceeding high-grade PIN, has been labeled
as atypical intraductal proliferation, atypical cribriform pro-
liferation, or atypical proliferation suspicious for IDC. A few
studies suggest that lesions currently considered suspicious, but
not definitive for IDC, are associated with more aggressive
cancer than high-grade PIN and are more reminiscent of IDC,
but more investigations are needed to eventually expand the
current IDC criteria.101 Apart from the common Gleason
growth patterns as previously mentioned, certain patterns
morphologically overlap or merge with cribriform, including
papillary and complex fused glands. Although these are cur-
rently assigned Gleason pattern 4, insufficient data exist on
their prognostic impact compared with the acknowledged cri-
briform, small fused, and poorly formed patterns.
Whereas invasive cribriform and IDC are used as
dichotomized criteria either being present or absent, percent
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Gleason patterns 4 and 5 represent continuous variables. As
extensively discussed for global and highest GS, it is not yet
clear whether percent Gleason patterns 4 and 5 have similar
impact as global measures for the entire case or should be
reported per biopsy site. Radiopathologic correlation of
mpMRI and biopsy sites might facilitate estimation of per-
centages within one tumor, and differentiate multifocal tumors
in the future. Another key development will be developing and
evaluating ML-based systems with patient outcome as the
standard of reference in contrast to the GS or GG. Several
techniques exist to inspect the visual cues used by such systems,
which can lead to the identification of prognostic factors such
as novel growth patterns or stromal features. These could help
drive future revisions of the ISUP grading scheme.
CONCLUSIONS
The 2019 ISUP consensus conference on prostatic
carcinoma grading acknowledges the important added value
of Gleason pattern quantity, minor Gleason patterns, invasive
cribriform carcinoma, and IDC, and provides recom-
mendations for their reporting. Furthermore, it summarizes the
grading challenges for the pathologist in the current era of
increasing mpMRI-targeted biopsies, and identifies unresolved
issues for further research. There is strong belief that novel ML
will support prostatic carcinoma grading in the near future. The
next steps should be integration of cribriform and IDC and
percent high-grade patterns in AI tools. The 2019 consensus
conference has not only updated reporting recommendations
with the latest state-of-the-art scientific evidence but also iden-
tified important objectives for future research.
APPENDIX
TABLE A1. Participants at the 2019 ISUP Consensus
Conference on Grading of Prostatic Carcinoma
Last Name First Name Country
Aachi Vijay UK
Adeniran Adebowale US
Agarwal Samita UK
Ahmed Khalid UK
Al Hussain Turki Saudi Arabia
Al-Jafari Mohammad UK
Beggan Caitlin US
Bertz Simone Germany
Burchett Ivan Australia
Butzow Anna Finland
Carvalho Rita Portugal
Castro Marilia Brazil
Chan Emily US
Cho Yong Mee Korea
Clouston David Australia
Cohen Penelope Australia
Coté Jean Francois France
Cubilla Antonio Paraguay
Cyll Karolina Norway
Delahunt Brett New Zealand
Dema Alis Romania
Diener Pierre-Andre Switzerland
Downes Michelle UK
Efremov Gennady Russia
El Sheikh Soha UK
TABLE A1. (continued)
Last Name First Name Country
Elversang Johanna Denmark
English John Canada
Euren Kristian Sweden
Fleischmann Achim Switzerland
Fursato Bungo US
Glaessgen Axel Sweden
Gomes Regina Brazil
Gonzales-Peramato Pilar Spain
Gréloz Vincent Switzerland
Grignon David US
Grobholz Rainer Switzerland
Haider Aiman UK
Hallam Lavinia Australia
Hamid Bushra UK
Hegyi Laszlo UK
Herrera Hernandez Loren US
Hussain Sundus UK
Iakovlev Vladimir Canada
Iakovleva Gaiane Canada
Isola Mariana Cecilia Argentina
Jimenez Rafael US
Jufe Laura Argentina
Koellermann Jens Germany
Kothari Archana UK
Kulla Andres UK
Leite Katia Brazil
Lemeshko Svetlana Russia
Lucia M. Scott US
Maclean Fiona Australia
Maheshwari Madhavi UK
Mchale Teresa Ireland
Muezzinoglu Bahar Turkey
Naidoo Prabha UK
Nesi Gabriella Italy
O’Rourke Declan UK
Okon Krzysztof Poland
Ozagari Ayse Aysim Turkey
Paner Gladell US
Perner Silke Germany
Pitchamuthu Hemamalini UK
Rao Madhu UK
Saker Zakaria Hamida Georgia
Sanz Julian Spain
Setiasti Anglita Yanti The Netherlands
Shah Nigam US
Simko Jeff US
Srigley John Canada
Susani Martin Austria
Suzigan Sueli Brazil
Szalay Ildiko Switzerland
Takahashi Hiroyuki Japan
Uchida Katsunori Japan
Vargiamidov Athanasina ?
Warren Anne UK
Yoon Ghilsuk Korea
Speakers
Mottet Nicholas France
Iczkowski Kenneth A. US
van Leenders Geert The Netherlands
Evans Andrew Canada
Kristiansen Glen Germany
Kweldam Charlotte The Netherlands
McKenney Jesse US
Melamed Jonathan US
Samaratunga Hema Australia
van der Kwast Theo Canada
Varma Murali UK
Schoots Ivo G. The Netherlands
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